References
- Hasan Shuja S, Asad D, Samad Parekh A. Sinopharm: an unavoidable contender in the struggle against Covid. [Letter to the Editor, Infection and Drug Resistance 2021]. Infect Drug Resist. 2021;14:3899–3900. doi:10.2147/IDR.S33846034588785
- Mascellino MT, Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021;14:3459–3476. doi:10.2147/IDR.S31572734511939
- WHO Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; May 7, 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-2021.1. Accessed October 13, 2021.
- Ars toscana edited by C. Silvestri, Health Regional Agency in Toscana (Italy) and C. Stasi. Available from: https://www.ars.toscana.it/2-articoli/4408-nuovo-coronavirus-vaccini-in-sperimentazione.html. Accessed October 23, 2021.
- Al Kaabi N, Zhang Y, Xia S, et al. Effect of inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a Randomized Clinical Trial. JAMA. 2021;326(1):35–45. doi:10.1001/jama.2021.856534037666
- A study to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero Cell) in healthy population aged 18 years old and above (COVID-19). ClinicalTrials.gov US National Library of Medicine (NIH). Available from: https://clinicaltrials.gov/ct2/show/record/NCT4510207. Accessed October 13, 2021.
- Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv. 2021. doi:10.1101/2021.09.02.21261735
- FDA News release FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations; September 22, 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations. Accessed October 13, 2021.